97
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dendritic cells (DCs) are required to initiate and sustain T cell-dependent anti-cancer immunity. However, tumors often evade immune control by crippling normal DC function. The endoplasmic reticulum (ER) stress response factor XBP1 promotes intrinsic tumor growth directly, but whether it also regulates the host anti-tumor immune response is not known. Here we show that constitutive activation of XBP1 in tumor-associated DCs (tDCs) drives ovarian cancer (OvCa) progression by blunting anti-tumor immunity. XBP1 activation, fueled by lipid peroxidation byproducts, induced a triglyceride biosynthetic program in tDCs leading to abnormal lipid accumulation and subsequent inhibition of tDC capacity to support anti-tumor T cells. Accordingly, DC-specific XBP1 deletion or selective nanoparticle-mediated XBP1 silencing in tDCs restored their immunostimulatory activity in situ and extended survival by evoking protective type 1 anti-tumor responses. Targeting the ER stress response should concomitantly inhibit tumor growth and enhance anti-cancer immunity, thus offering a unique approach to cancer immunotherapy.

          Related collections

          Author and article information

          Journal
          Cell
          Cell
          1097-4172
          0092-8674
          Jun 18 2015
          : 161
          : 7
          Affiliations
          [1 ] Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA.
          [2 ] Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
          [3 ] Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
          [4 ] Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA.
          [5 ] Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA; Harvard Graduate Program in Immunology, Harvard University, Boston, MA 02115, USA.
          [6 ] Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY 10065, USA.
          [7 ] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
          [8 ] Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: lglimche@med.cornell.edu.
          Article
          S0092-8674(15)00575-9 NIHMS691029
          10.1016/j.cell.2015.05.025
          26073941
          fbedfa7d-23fd-41fa-94d7-f1420db75d2f
          Copyright © 2015 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article

          Related Documents Log